Loading…
Alnylam Pharmaceuticals, Inc. is projected to rise to $391.67 by 2027, a +31% move from its current price of $298.76. ALNY is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $293.38 | $299.05 | $304.83 | +0.10% |
| Jul 15 | $291.34 | $299.34 | $307.55 | +0.19% |
| Jul 16 | $289.86 | $299.63 | $309.73 | +0.29% |
| Jul 17 | $288.65 | $299.92 | $311.62 | +0.39% |
| Jul 18 | $287.63 | $300.20 | $313.33 | +0.48% |
| Jul 19 | $286.73 | $300.49 | $314.92 | +0.58% |
| Jul 20 | $285.93 | $300.78 | $316.41 | +0.68% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $285.93 | $300.78 | $316.41 | +0.68% |
| Week 2 | $281.89 | $302.82 | $325.31 | +1.36% |
| Week 3 | $279.27 | $304.87 | $332.82 | +2.05% |
| Week 4 | $277.38 | $306.94 | $339.66 | +2.74% |
| Week 5 | $275.94 | $309.02 | $346.07 | +3.43% |
| Week 6 | $274.82 | $311.11 | $352.20 | +4.14% |
| Week 7 | $273.95 | $313.22 | $358.13 | +4.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on RNA interference in the United States, Europe, and internationally. It operates in the Healthcare sector and is founded to advance RNA interference–based medicines for various diseases.
The company has a portfolio of approved therapies including ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trials (Nucresiran, Zilebesiran, Cemdisiran, Elebsiran) and Phase 2/Phase 1 programs across metabolic, cardiovascular, and neurodegenerative targets. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
It has collaborations with Regeneron Pharmaceuticals, Roche Holding AG, Sanofi S.A., Novartis AG, PeptiDream, Dicerna Pharmaceuticals, and Ionis Pharmaceuticals.
ALNY trades as a healthcare stock with a current price of $298.76 and a market capitalization of $39.89B, ranking 375 by size. The 30-day price action sits within a range of $263.35 to $338.94, reflecting a modestly constructive near-term setup.
Technically, the stock shows a neutral near-term posture with a 14-day RSI of 50. The 50-day simple moving average sits at $296.41 and the 200-day moving average at $363.39, suggesting potential consolidation around the nearer SMA while longer-term resistance sits near $323.50 and support near $278.09. The stock’s volatility runs high at about 40% annualized, underscoring substantial price swings within the current framework.
Overall, the forecast paints a long-run bullish trajectory with substantial upside potential. The 2026-2050 path shows rising average prices and meaningful ROIs in later years, subject to market and clinical development risks. The current level aligns with the near-term range while longer-term projections suggest a strong upside if the growth drivers materialize.
A major floor 14.7% below — a decisive break under it would weaken the trend.
The nearest floor, 6.9% below — buyers have tended to step in here.
The nearest ceiling, 8.3% above — a clean break opens room to run.
A major ceiling 15.7% above — clearing it would confirm fresh momentum.
Key ALNY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALNY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $313.94 | Sell | $309.20 | Sell |
| MA 10 | $307.01 | Sell | $306.78 | Sell |
| MA 20 | $296.73 | Buy | $302.05 | Sell |
| MA 50 | $296.41 | Buy | $301.91 | Sell |
| MA 100 | $309.01 | Sell | $315.07 | Sell |
| MA 200 | $363.39 | Sell | $331.88 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.69 | Neutral |
| Stoch RSI (14) | 12.91 | Buy |
| CCI (20) | 12.15 | Neutral |
| Williams %R (14) | -66.70 | Info |
| MACD (12,26,9) | 1.95 | Buy |
| ROC (12) | 3.67 | Buy |
| Bollinger %B (20,2) | 0.54 | Neutral |
| Stochastic %K (14) | 33.30 | Neutral |
| TRIX (15) | 0.13 | Buy |
| Awesome (5,34) | 17.09 | Buy |
| Ultimate (7,14,28) | 52.39 | Neutral |
| Momentum (10) | 5.59 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 316.81 | Sell |
| ADX (14) | 15.44 | Neutral |
| ATR (14) | 5.67 | Info |
The near-term technical picture is neutral, with RSI at 50 and a price range over the last 30 days between $263.35 and $338.94.
The 50-day moving average is $296.41, versus the 200-day moving average at $363.39, indicating a potential to hover near the short-term support and resistance levels. Immediate support is at $278.09 and resistance at $323.50, framing a cautious, range-bound posture in the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $278.09 | $298.76 | $433.75 | 0% | Neutral | |
| $320.47 | $391.67 | $500.70 | +31% | Bullish | |
| $351.78 | $438.15 | $575.48 | +47% | Bullish | |
| $374.41 | $473.66 | $635.56 | +59% | Bullish | |
| $382.15 | $490.10 | $669.63 | +64% | Bullish | |
| $407.60 | $529.23 | $734.67 | +77% | Bullish | |
| $454.59 | $597.04 | $840.75 | +100% | Bullish | |
| $532.50 | $706.86 | $1,008.45 | +137% | Bullish | |
| $572.86 | $768.14 | $1,109.15 | +157% | Bullish | |
| $578.62 | $783.34 | $1,143.85 | +162% | Bullish | |
| $817.79 | $1,155.66 | $1,769.46 | +287% | Bullish | |
| $1,380.26 | $2,094.86 | $3,440.94 | +601% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $278.09 | $298.76 | $357.41 | +0.00% |
| August 2026 | $270.57 | $316.79 | $379.00 | +6.04% |
| September 2026 | $277.28 | $326.24 | $393.40 | +2.98% |
| October 2026 | $278.74 | $329.32 | $399.78 | +0.95% |
| November 2026 | $286.90 | $340.17 | $415.26 | +3.29% |
| December 2026 | $297.16 | $353.48 | $433.75 | +3.91% |
Click any year to see its month-by-month ALNY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ALNY to range from $278.09 to $433.75 through 2026. The $298.76 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ALNY price prediction for 2027 points to an average of $391.67 (low $320.47, high $500.70) — a potential gain of +31% on today's $298.76. Momentum favours further upside here.
In 2028, ALNY is projected to trade between $351.78 and $575.48, averaging $438.15 — a potential gain of +47% from today's $298.76. That is up +12% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Alnylam Pharmaceuticals, Inc.'s 2029 outlook centres on $473.66, within a $374.41 to $635.56 range. That is up +8% on the projected 2028 average. That marks a +59% change versus current levels. Momentum favours further upside here.
By 2030, ALNY could reach as high as $669.63, with a base case around $490.10 and support toward $382.15 — roughly +64% from $298.76. Buyers look set to stay in control over this stretch.
Expect ALNY to range from $407.60 to $734.67 through 2031. The $529.23 average target implies a +77% move from current prices. That is up +8% on the projected 2030 average. Momentum favours further upside here.
The ALNY price prediction for 2032 points to an average of $597.04 (low $454.59, high $840.75) — a potential gain of +100% on today's $298.76. Buyers look set to stay in control over this stretch.
In 2033, ALNY is projected to trade between $532.50 and $1,008.45, averaging $706.86 — a potential gain of +137% from today's $298.76. That is up +18% on the projected 2032 average. Momentum favours further upside here.
Alnylam Pharmaceuticals, Inc.'s 2034 outlook centres on $768.14, within a $572.86 to $1,109.15 range. That is up +9% on the projected 2033 average. That marks a +157% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ALNY could reach as high as $1,143.85, with a base case around $783.34 and support toward $578.62 — roughly +162% from $298.76. Momentum favours further upside here.
Expect ALNY to range from $817.79 to $1,769.46 through 2040. The $1,155.66 average target implies a +287% move from current prices. That is up +48% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ALNY price prediction for 2050 points to an average of $2,094.86 (low $1,380.26, high $3,440.94) — a potential gain of +601% on today's $298.76. Momentum favours further upside here.
Investing $1,000 in ALNY today (≈ 3.347168 ALNY) could be worth
$7,011.84
+$6,011.84 (+601%) by 2050 · US Dollar
Based on the average projected ALNY price of $2,094.86 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALNYwould be worth at today's price.
$1,000 invested in ALNY on Jul 10, 2025 (≈ 3.09943 ALNY) would be worth
$925.99
-$74.01 (-7.4%) today · 0.93× · US Dollar
Based on a ALNY entry price of $322.64 vs. today's $298.76.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $312.78 | $955.18 | -4.5% |
| 1 month ago | $291.22 | $1,025.89 | +2.6% |
| 3 months ago | $322.11 | $927.51 | -7.2% |
| 6 months ago | $370.91 | $805.48 | -19.5% |
| 1 year ago | $322.64 | $925.99 | -7.4% |
| All time (5.0y) ago | $170.34 | $1,753.9 | +75.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALNY forecast.
Our base-case forecast reaches $600.00 around 2033.
Implied market cap at $600.00: $80.11B
The multi-year forecast shows a bullish arc with accelerating upside. In 2026 the avg price is $298.76 with a min of $278.09 and a max of $434.11 and ROI of 0, reflecting a neutral start. From 2027 onward, the averages rise to $391.43 (ROI 31), $438.51 (46.8), $473.95 (58.6), and $489.67 (63.9) by 2030, with the sentiment turning bullish.
The path continues higher through 2031 ($529.62, ROI 77.3) and 2032 ($597.49, ROI 100), then stronger into 2033 ($706.64, ROI 136.5), 2034 ($768.74, ROI 157.3), and 2035 ($783.23, ROI 162.2).
By 2040, the average price is forecast at $1,156.89 (ROI 287.2) with a max of $1,771.37, and by 2050 the average reaches $2,095.05 (ROI 601.3) with a max of $3,441.31. The yearly max values extend to $1,008.18 in 2033, $1,110.05 in 2034, $1,143.72 in 2035, $1,771.37 in 2040, and $3,441.31 in 2050, underscoring substantial upside potential over the long horizon. While these are estimates, they illustrate a clear bullish drift supported by the projected price path and ROIs.
Tap a question to reveal the answer.
The 2030 forecast shows an avg of $489.67 with a min of $381.80 and a max of $669.07; ROI 63.9; sentiment BULLISH.
Forecasts from 2026 onward show a bullish trajectory with rising averages and positive ROIs: 2026 avg $298.76 (ROI 0), 2027 avg $391.43 (ROI 31), 2028 avg $438.51 (ROI 46.8), 2029 avg $473.95 (ROI 58.6), and 2030 avg $489.67 (ROI 63.9). The current price is $298.76 with a market cap of $39.89B and neutral near-term signals. These are estimates, not guarantees.
Yes. The forecast max values exceed $1,000: 2033 max $1,008.18, 2034 max $1,110.05, and 2035 max $1,143.72.
Current price is $298.76 and market cap is $39.89B. The stock is ranked 375 by market cap size.
The 30-day range is $263.35 to $338.94. RSI is 50, SMA50 is $296.41, SMA200 is $363.39. Support is $278.09 and resistance is $323.50, with annualized volatility around 40%.
Alnylam Pharmaceuticals, Inc. Community Discussion
0Share your Alnylam Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.